PhD, University of Michigan. Postdoctoral training, Salk Institute and Oregon Health & Science University. Directed underlying research at Cornell University Medical College and Texas A&M University. Expertise on melanocortin control of emotional states built over 17 years.

PhD, Neuroscience, Texas A&M University
Extensive expertise in melanocortin control of emotional states.

27 years in pharmaceutical product development, and growth and commercialization of early-stage companies. Recently served as commercial leader for Avanir Pharmaceuticals (acquired by Otsuka). Previously, held commercial and non-commercial roles at Amylin (acquired by AstraZenena, BMS), Pharmacia (aquired by Pfizer), and Eli Lilly. Has been involved in developing and marketing some of the industry's blockbuster prescription products.

Dr. Tolbert has 27 years in clinical pharmacology and regulatory affairs in the pharmaceutical industry. He is the Director of Clinical Trials in the U.S. for Lundbeck. Previously, he held positions at Takeda Pharmaceuticals and Pfizer Corporation.

Dr. Hunter has 24 yrs of animal and human drug development experience with NASA, Pfizer, Elanco, Parnell, Provetica, and One Medicine Consulting. Contributed to the approvals for Revolution®, Dectomax®, Micotil®, Ovugel®, and Pulmotil®. Expertise in PK/PD, interspecies allometry, drug metabolism, bioequivalence, and tissue residues.